Ann: Trading Halt, page-20

Even at a premium we've still been bent over. If the name of the game is sell the company in 2026-2027 pending data, the dilution is going to hurt the end game.

Gaz's whole spiel has been phase 2 data is a point of inflection. Companies with positive phase 2 data can jump 5-10 X. We have a cash runway and will have data from 4 phase 2 trials within that cash runaway. Anyone of these trials could see significant SP appreciation.

They are spending $1 mill a month, had $7 mill cash on hand 28th of April. Additional $6mill expected from acquirer of MBU and another $1 mill when they give the keys back. $5.2 million incoming from FY 2023 for R&D tax credits.

The previous years tax credits came in December. I'm wondering if the funds from the sale of MBU have been held up and they needed to fill the tank prior to December.